It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

San Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) at Mitocon 2026 - a leadi ...

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper unde ...

Core Insights - Janux Therapeutics (JANX) has entered a strategic collaboration and exclusive global license agreement with Bristol Myers Squibb (BMY) to develop tumor-activated therapies for solid tumors [2][4] - The partnership validates Janux's proprietary tumor-activated immunotherapy platforms and enhances its presence in the oncology sector [2][12] Financial Aspects - Janux is eligible for up to $50 million in upfront and near-term milestone payments, with potential additional milestones totaling approximately $800 million [5][9] - The deal allows Janux to leverage its platform expertise while transferring later-stage development risks to BMY, a large pharmaceutical partner [10] Development and Commercialization - Janux will lead preclinical development until the IND submission, after which BMY will assume responsibility for clinical development and global commercialization [6][10] - Janux will remain involved through the completion of the first phase I study, ensuring continuity in the development process [6] Clinical Pipeline - Janux currently has two tumor-activated T cell engagers in clinical development targeting prostate-specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) across various solid tumors [11] - The collaboration with BMY serves as a validation of Janux's tumor-activated approach and enhances the credibility of its broader pipeline strategy [12]

SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose escalation da ...

LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has authorized a single-patient expanded access (compassionate use) Investigational New Drug (IND) application submitted by Pedram Hamrah, MD, at the University of South Florida, for the us ...

Most microcap biopharma stocks are binary bets. You either get a drug approval and a buyout or you get a failed trial and a zero. Journey Medical ( DERM ) is different, and I thinkI'm a fundamental investor who targets situations where the market has pushed a company’s valuation far out of line with its underlying economics. My professional background in corporate financial analysis has deeply shaped my investment perspective, leading me to focus intensely on cash flow durability, balance sheet strength, an ...

Summary of Tivic Health Conference Call Company Overview - **Company**: Tivic Health - **Ticker Symbol**: TIVC (Nasdaq) - **Focus**: Transitioning into a biopharmaceutical company with late-stage assets, particularly in radiation treatment and oncology [1][2] Core Points and Arguments - **Transformation**: Tivic Health has completed a major overhaul, focusing on harnessing the immune system to improve clinical outcomes, particularly in radiation treatment [2] - **Intolamod**: - Licensed drug with significant prior investment ($140 million) and government support ($36 million) aimed at treating acute radiation syndrome [3] - Potential applications in oncology, with a well-characterized mechanism of action supported by over 40 studies [4] - **Market Opportunity**: - Current standard of care in the acute radiation syndrome market is valued at $9.4 billion, primarily addressing blood disorders from radiation exposure [5] - Intolamod could replace existing G-CSF drugs and provide protective benefits while supporting regeneration of fast-growing cells [6] - **Commercialization Milestones**: - Successful scaling of manufacturing from small batch to 200x, maintaining or exceeding purity and potency levels [8] - Plans to file a Biologics License Application (BLA) with the FDA, with Fast Track and Orphan Drug Designation already secured [8] - **Government Interest**: Significant interest from the U.S. government as a medical countermeasure for nuclear disasters, alongside oncology applications [9] - **Strategic Moves**: - Acquisition of manufacturing assets to bring production in-house, ensuring cGMP manufacturing access and reducing time to market [10] - Establishment of a contract development and manufacturing organization (CDMO) for phase one and two biologics, creating an additional revenue stream [11] - **Financial Position**: Recently closed a financing package allowing access to up to $75 million, targeting multiple high-value therapeutic inflection points within the next 18 to 24 months [12] Additional Important Content - **Regulatory Pathway**: The company is drafting its BLA and anticipates starting investigator-led trials in oncology applications this year [9] - **Partnership Opportunities**: Intolamod's unique position in both acute radiation syndrome and oncology creates real partnering opportunities as the company progresses [10] - **Location Advantage**: The San Antonio facility is strategically positioned to serve U.S. government requirements, with proximity to military bases and airports for emergency product transport [11]

Israel 2834 Not Applicable (Primary Standard Industrial Classification Code Number) As filed with the Securities and Exchange Commission on January 22, 2026 Registration No. 333-292528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction o ...

Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial r ...